Parameter | n (%) |
---|---|
Histological diagnosis* | Â |
   IDC | 67 (70.5) |
   ILC | 16 (16.8) |
   Others | 12 (12.6) |
Histological grade | Â |
   I | 29 (55.8) |
   II | 19 (36.5) |
   III | 4 (7.7) |
Tumor size (T) | Â |
   T2 | 76 (80.0) |
   T3-T4 | 19 (20.0) |
Lymph node involvement (N) | Â |
   N0 | 76 (80.0) |
   N1-2 | 19 (20.0) |
Stage | Â |
   IIa | 65 (68.4) |
   IIb | 20 (21.1) |
   IIIa-IIIb | 10 (10.5) |
ER | Â |
   Negative | 5 (5.3) |
   10-40% | 8 (8.4) |
   40-70% | 25 (26.3) |
   > 70% | 57 (60.0) |
PgR | Â |
   Negative | 28 (29.5) |
   10-40% | 18 (18.9) |
   40-70% | 24 (25.3) |
   > 70% | 25 (26.3) |
HR** | Â |
   ≤ 40% | 10 (10.5) |
   > 40% | 85 (89.5) |
HER2 | Â |
   Negative | 39 (41.1) |
   + | 24 (25.3) |
   ++ | 22 (23.2) |
   +++ | 10 (10.5) |
Ki67 | Â |
   Negative | 40 (55.6) |
   Positive | 32 (44.4) |
Response to letrozole | Â |
   Non responders | 60 (63.2) |
   Responders | 35 (36.8) |
Progression status | Â |
   No progression | 77 (81.1) |
   Progression | 18 (18.9) |
Surgery status | Â |
   No surgery | 30 (32.0) |
   Surgery | 65 (68.0) |